Breast Journal最新文献

{"title":"Programmed Death Ligand 1 (PDL1) Expression in Neoadjuvant Triple-Negative Breast Cancer: Association With Chemotherapy Response and Residual Cancer Burden","authors":"Atif Ali Hashmi, Noreen Wahid, Ghazala Mudassir, Muhammad Irfan, Umair Arshad Malik, Erum Yousuf Khan, Syed Muhammad Abu Bakar, Naveen Faridi","doi":"10.1155/tbj/8856567","DOIUrl":"https://doi.org/10.1155/tbj/8856567","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Programmed death ligand 1 (PDL1) expression in tumors is linked to immune evasion in various cancers, making these patients potential candidates for PDL1 inhibitors. Although immune checkpoint blockade therapy has gained approval for breast cancer treatment, especially triple-negative breast cancer (TNBC), there is a lack of PDL1 expression data in Pakistani breast cancer patients. In our study, PDL1 expression was assessed in TNBC to determine eligibility for PDL1 inhibitors. Our study aimed to evaluate the frequency of PDL1 expression in TNBC. We also examined how PDL1 expression correlates with clinicopathological characteristics and prognostic factors in patients with TNBC. Moreover, the association of neoadjuvant chemotherapy response with PDL1 expression was also evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This cross-sectional study was conducted at the Liaquat National Hospital Histopathology Department from January 2022 to June 2023. A total of 128 biopsy-proven cases of TNBCs were administered neoadjuvant chemotherapy before surgery during this period. PDL1 immunohistochemical staining was performed on prechemotherapy needle biopsies. Expression was determined using the combined positive score (CPS). CPS is the number of PDL1-stained cells (tumor cells, lymphocytes, and macrophages) divided by the total number of viable tumor cells multiplied by 100. Cases with CPS ≥ 10 were considered PDL1-positive.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Complete pathological response (pCR) was observed in 32.8% (<i>n</i> = 42) of cases. PDL1 expression was observed in 18.8% (<i>n</i> = 24) of cases. The majority of cases showed a high residual cancer burden (RCB-III) (<i>n</i> = 53, 41.4%). A significant association was noted between PDL1 expression and neoadjuvant chemotherapy response (<i>p</i> < 0.01). PDL1-positive cases had a higher pCR (<i>n</i> = 16, 66.7%) than PDL1-negative cases (<i>n</i> = 26, 25%). PDL1-positive cases showed a lower frequency of RCB-II-III (RCB-II: 8.3%; RCB-III: 0%) than PDL1-negative cases (RCB-II: 25%; RCB-III: 51%), with a significant <i>p</i> value (<i>p</i> < 0.01).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Overall, PDL1 expression was low in TNBC cases in our study; however, identifying these cases is important to identify those that can benefit from immunotherapy. We found a significant association of PDL1 expression with neoadjuvant chemotherapy response and RCB. Moreover, PDL1 positivity was associated with lower Ki67 index and older age. Therefore, we reco","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/8856567","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145224182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Era “or Error” of Second Localization Procedures","authors":"Nicole Nelson,&nbsp;Jennifer Den,&nbsp;Roi Weiser,&nbsp;Biai Digbeu,&nbsp;H. Colleen Silva,&nbsp;Angelica S. Robinson,&nbsp;Flavia Poselman,&nbsp;V. Suzanne Klimberg","doi":"10.1155/tbj/6391905","DOIUrl":"https://doi.org/10.1155/tbj/6391905","url":null,"abstract":"<p><b>Background:</b> Clips placed after core needle biopsy are often several millimeters to centimeters from the biopsy cavity. Radiofrequency and radar (R) localization involve a second localization procedure based on the prior clip placement, potentially compounding the distance from the area localized to the original biopsy site. Fluoroscopic intraoperative neoplasm detection (FIND) obviates the need for a second localization by using intraoperative fluoroscopy to localize the original biopsy clip. We hypothesized that intraoperative localization using FIND is feasible and may result in fewer positive margins.</p><p><b>Methods:</b> A retrospective review was performed of patients with nonpalpable malignancy who underwent partial mastectomy from September 2016 to August 2023. Results were compared between patients who underwent R localization vs. FIND. The Pythagorean theorem was used to calculate the distance in space between the biopsy clip and the R localization device. Chi-square was used to calculate the two-tailed <i>p</i> value.</p><p><b>Results:</b> We identified 219 patients: 161 localized with FIND and 55 with R. Three percent (6 out of 161) of the patients with FIND and 12% (7 out of 55) of the patients with R had positive margins (<i>p</i> = 0.01). The average distance between the R device and biopsy clip in patients with positive margins was 19.1 mm, and with negative margins, it was 12.45 mm (<i>p</i> = 0.09).</p><p><b>Conclusions:</b> The positive margin rate with R localization was significantly greater than with FIND. The positive margin rate trended toward increased distance from the localization device to the biopsy clip. Eliminating the second localization decreases painful procedures for the patient and may result in improved tumor-free margins.</p>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/6391905","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145224257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Life Postdiagnosis: Female Adult Breast Cancer Survivors’ Experience With Physical Activity—A Qualitative Systematic Review","authors":"Neeve Brown,&nbsp;Fiona Muirhead","doi":"10.1155/tbj/6926093","DOIUrl":"https://doi.org/10.1155/tbj/6926093","url":null,"abstract":"<p><b>Background:</b> With increasing survival rates of breast cancer, there is a need for more research to understand the experiences of survivors. Previous quantitative studies have shown that physical activity can be beneficial for breast cancer survivors. However, a qualitative perspective is essential to create appropriate adaptations for this population. This study aims to develop a deeper understanding of the experiences of female adult breast cancer survivors with physical activity in their postdiagnosis lifestyle.</p><p><b>Methods:</b> This study followed a qualitative systematic review methodology. In January 2024, six databases (APA PsycInfo, CINAHL Plus, OVID Medline, Scopus, SPORTDiscus and Sports Medicine an Education Index) were searched using aim-specific key terms. Ten studies, comprising a total sample of 200 participants, met the inclusion criteria. Quality appraisal, data extraction and synthesis stages were conducted.</p><p><b>Results:</b> Five main themes emerged during the synthesis stage: (1) Outcomes of Physical Activity Participation, (2) Barriers to Physical Activity, (3) Postdiagnosis Balancing Act, (4) Needs for Future Physical Activity Programs and (5) Next Steps for Breast Cancer Survivors. Additionally, 15 subthemes were identified.</p><p><b>Conclusion:</b> Overall, breast cancer survivors reported positive experiences with physical activity, leading to a desire to maintain an active lifestyle. However, barriers such as treatment side effects, unmet needs for advice from health services and challenges in daily life postdiagnosis were identified. Future research should explore the implementation of specific national guidelines and recommendations for survivors postdiagnosis to overcome these barriers and enhance the quality of survivorship care.</p>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/6926093","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145146728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skin Involvement of Idiopathic Granulomatous Mastitis: Sonographic, Clinical, and Histopathological Features","authors":"Fatih Işık,&nbsp;Erdal Pala,&nbsp;Fatih Alper,&nbsp;Sevilay Ozmen,&nbsp;Elif Demirci,&nbsp;Hasan Abbasguliyev,&nbsp;Müfide Nuran Akçay","doi":"10.1155/tbj/7224219","DOIUrl":"https://doi.org/10.1155/tbj/7224219","url":null,"abstract":"<p><b>Objectives:</b> Idiopathic granulomatous mastitis (IGM) is a rare benign breast disease in which cutaneous involvement is insufficiently characterized. This study aimed to evaluate the sonographic, clinical, and histopathological features of skin manifestations in IGM.</p><p><b>Methods:</b> We retrospectively analyzed 138 women with biopsy-proven IGM who underwent breast and skin ultrasonography between 2023 and 2024. Clinical cutaneous findings were documented, and 14 patients with visible skin lesions underwent additional punch biopsy for histopathological evaluation. Sonographic and clinical features were stratified according to symptom duration (0–3, 4–6, 7–9, and ≥ 10 weeks).</p><p><b>Results:</b> Cutaneous lesions were identified in 84/138 patients (60.9%). Sonographic findings followed a sequential distribution: fibrous echogenicity loss in early disease (11/14, 78.6%), vacuolar structures at 4–6 weeks (11/19, 57.9%), dermo-subcutaneous blurring at 7–9 weeks (9/34, 26.5%), and advanced features such as fistula formation (11/17, 64.7%) and dermo-subcutaneous disruption (11/17, 64.7%) beyond 10 weeks. Clinical findings paralleled imaging, with erythema and papulopustular lesions predominating early (13/14, 92.9%), erythema nodosum peaking at 4–6 weeks (7/19, 36.8%), and ulceration and fistula formation emerging after ≥ 7 weeks (11/17, 64.7% at ≥ 10 weeks). Histopathological analysis of 14 skin biopsies demonstrated nonspecific inflammatory changes without granuloma formation.</p><p><b>Conclusions:</b> IGM demonstrates sequential sonographic and clinical cutaneous patterns associated with symptom duration. Early erythematous and papulopustular changes progress to ulceration and fistula formation in prolonged disease. Although supportive in suggesting cutaneous involvement, these features are not diagnostic, and histopathological confirmation remains essential. Prospective studies are warranted to further define the clinical and histological course of cutaneous changes in IGM.</p>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/7224219","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145146474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Primary bilateral breast lymphoma in an elder male patient”","authors":"","doi":"10.1155/tbj/9821303","DOIUrl":"https://doi.org/10.1155/tbj/9821303","url":null,"abstract":"<p>Y. Bozkaya, F. Oz Puyan, and B. Bimboga, “Primary bilateral breast lymphoma in an elder male patient,” <i>The Breast Journal</i> 25, no. 5 (2019): 1008-1009, https://doi.org/10.1111/tbj.13394.</p><p>In the article titled “Primary bilateral breast lymphoma in an elder male patient,” there was a spelling error in author Busem Binboga’s name in the author list, where Busem Bimboga should have read Busem Binboga. The corrected author list and affiliation list should be as follows:</p><p>Yakup Bozkaya¹, Fulya Oz Puyan², Busem Binboga²</p><p>¹Clinic of Medical Oncology, Edirne State Hospital, Edirne, Turkey</p><p>²Department of Pathology, Faculty of Medicine, Trakya University, Edirne, Turkey</p><p>We apologize for this error.</p>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/9821303","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145101896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Analysis of Conventional Ultrasound and Contrast-Enhanced Ultrasound Features of Pseudoangiomatous Stromal Hyperplasia”","authors":"","doi":"10.1155/tbj/9801706","DOIUrl":"https://doi.org/10.1155/tbj/9801706","url":null,"abstract":"<p>H. Li, Q. Niu, C. Jia, et al., “Analysis of Conventional Ultrasound and Contrast-Enhanced Ultrasound Features of Pseudoangiomatous Stromal Hyperplasia,” <i>The Breast Journal</i> 2025 (2025): 6070736, https://doi.org/10.1155/tbj/6070736.</p><p>In the article titled “Analysis of Conventional Ultrasound and Contrast-Enhanced Ultrasound Features of Pseudoangiomatous Stromal Hyperplasia,” there was an error in affiliations 1 and 2 order. The corrected author list and affiliation list should be as follows:</p><p>Hui Li^1,2, Qinghua Niu¹, Chao Jia¹, Gaoxiang Fan¹, Long Liu¹, Gang Li¹, Penglin Zou¹, Rong Wu¹, Lianfang Du¹, Jing Wang³, and Qiusheng Shi¹</p><p>¹Department of Ultrasound, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China</p><p>²Department of Ultrasound, Huashan Hospital, Fudan University, Shanghai, China</p><p>³Department of Pathology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China</p><p>We apologize for this error.</p>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/9801706","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145101895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “The Quest for Outpatient Mastectomy in COVID-19 Era: Barriers and Facilitators”","authors":"","doi":"10.1155/tbj/9847254","DOIUrl":"https://doi.org/10.1155/tbj/9847254","url":null,"abstract":"<p>L. J. van Zeelst, R. Derksen, C. H. W. Wijers, et al., “The Quest for Outpatient Mastectomy in COVID-19 Era: Barriers and Facilitators,” <i>The Breast Journal</i> 2022 (2022): 1863519, https://doi.org/10.1155/2022/1863519.</p><p>In the article titled “The Quest for Outpatient Mastectomy in COVID-19 Era: Barriers and Facilitators” there were errors in Figure 1 and Table 1.</p><p>In Figure 1 legends, inpatient mastectomy and outpatient mastectomy were attributed to the wrong colour. The corrected Figure 1 is shown below.</p><p>In Table 1, values in the polypharmacy rows were incorrect. The corrected Table 1 is shown below.</p><p>We apologize for this error.</p>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/9847254","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145101691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Morphological Assessment of Breast Lesions With Type 2 Dynamic Curves Using DWI and T2WI Based on Breast Imaging Reporting and Data System Lexicon Descriptors","authors":"Liying Zhang,&nbsp;Gongsheng Zhu,&nbsp;Kefan Wang,&nbsp;Tongzhen Zhang,&nbsp;Lin Lu,&nbsp;Xin Zhao","doi":"10.1155/tbj/9957678","DOIUrl":"https://doi.org/10.1155/tbj/9957678","url":null,"abstract":"<p><b>Purpose:</b> This study aimed to qualitatively assess the added diagnostic value of diffusion-weighted imaging (DWI) and T2-weighted imaging (T2WI), using Breast Imaging Reporting and Data System (BI-RADS) lexicon descriptors, in evaluating breast lesions with type 2 dynamic curves.</p><p><b>Materials and Methods:</b> We retrospectively reviewed 181 breast lesions with type 2 dynamic curves in 181 consecutive patients who underwent 3-Tesla (3-T) magnetic resonance imaging (MRI). Trained radiologists assessed the morphological features of the lesions on dynamic contrast-enhanced (DCE) MRI, DWI, and T2WI using BI-RADS lexicon descriptors and measured the apparent diffusion coefficient (ADC). Statistical analysis was performed to compare variables in lesion type groups (mass-like group vs. nonmass-like group). Diagnostic performance was evaluated using the area under the receiver operating characteristic curve (AUC) and the DeLong test, with statistical significance at <i>p</i> &lt; 0.05.</p><p><b>Results:</b> In mass-like lesions, all morphological parameters significantly distinguished benign from malignant lesions on DCE, DWI, and T2WI (all <i>p</i> &lt; 0.05). ADC values also showed significant differences (<i>p</i> &lt; 0.05). The combined approach (DCE + DWI + T2WI) yielded the highest AUC (0.895), significantly outperforming the individual methods (all <i>p</i> &lt; 0.05). In nonmass-like lesions, no parameter significantly predicted malignancy (all <i>p</i> &gt; 0.05).</p><p><b>Conclusion:</b> The addition of DWI and T2WI, interpreted using the BI-RADS lexicon descriptors, enhances the differential diagnosis of breast lesions with type 2 dynamic curves.</p>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/9957678","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144997896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Applicability of Oncotype DX Testing in a Diverse Breast Cancer Population in Hawaii","authors":"Kyle Xia,&nbsp;Eileen Chen,&nbsp;Roxana Hu,&nbsp;Ian Pagano,&nbsp;Jami Fukui","doi":"10.1155/tbj/9104103","DOIUrl":"https://doi.org/10.1155/tbj/9104103","url":null,"abstract":"<p><b>Purpose:</b> The Oncotype DX test is standardly used for patients with early-stage, hormone-receptor–positive, HER2-negative breast cancers to determine the benefit from chemotherapy and the likelihood of distant recurrence. The relationship between Oncotype DX recurrence scores and race/ethnicity is still being studied. This retrospective study aims to evaluate the relationship between Oncotype DX recurrence scores, race/ethnicity, and clinicopathological factors and to support the applicability of the Oncotype DX test for a diverse breast cancer population of Hawaii.</p><p><b>Materials and Methods:</b> We evaluated 879 breast cancer cases diagnosed from January 2018–March 2022 within a major health system in Hawaii, 600 of which received Oncotype DX recurrence scores to provide prognostic and therapy-predictive information based on NCCN guidelines. Linear regression with both univariable (unadjusted) and multivariable (adjusted for all other variables) models was run on the 600 breast cancer cases that received Oncotype DX recurrence scores. The predictor variables were age at diagnosis, race, tumor size, ER/PR status, and histology.</p><p><b>Results:</b> On multivariable analysis, we found statically significant differences in Oncotype DX recurrence scores according to age (60–69 vs. 18–49, <i>p</i> = 0.01), ER/PR status (PR-positive vs. PR-negative, <i>p</i> &lt; 0.0001), histology (other vs. ductal, <i>p</i> = 0.004), and tumor size (2–5 cm vs. 0-1 cm, <i>p</i> = 0.0003). We found no significant differences in Oncotype DX recurrence scores according to race/ethnicity.</p><p><b>Conclusion:</b> Our findings indicate that Oncotype DX recurrence scores are not variable according to race/ethnicity, highlighting the need for further research to understand the known disparities in breast cancer outcomes among different racial/ethnic groups. Our study supports the correlation between Oncotype DX recurrence scores and other factors and aligns with established prognostic trends for these variables in a diverse population. This study supports the applicability for the Oncotype DX test in a diverse breast cancer population of Hawaii.</p>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/9104103","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Efficacy of HLX02-Based Neoadjuvant Therapy in HER2-Positive Breast Cancer: Clinical Insights and Future Directions","authors":"Zhengzhi Zhu,&nbsp;Jing Wang,&nbsp;Shikai Hong,&nbsp;Hong Gao,&nbsp;Jianjun Liu,&nbsp;Kuojun Ren,&nbsp;Shuhan Wang,&nbsp;Shengying Wang,&nbsp;Guoping Sun","doi":"10.1155/tbj/1653319","DOIUrl":"https://doi.org/10.1155/tbj/1653319","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> The efficacy of HLX02, a trastuzumab biosimilar, in combination with chemotherapy for treating metastatic breast cancer (BC) has been established as equivalent to the reference Herceptin. This study aimed to assess the treatment response of HLX02-based neoadjuvant therapy in HER2-positive BC, with a focus on HR-positive versus HR-negative subgroups. Additionally, we investigated the potential role of a CDK4/6 inhibitor in combination with anti-HER2 therapy.</p>\u0000 <p><b>Methods:</b> This retrospective study included HER2-positive BC patients who received HLX02-based neoadjuvant therapy followed by curative surgery at Anhui Provincial Cancer Hospital between March 2021 and August 2023. Pathological complete response (pCR) rates were analyzed, and subgroup analyses evaluated predictors of pCR. In vitro experiments using BT-474 and MCF-7 cell lines assessed the effects of combining CDK4/6 inhibitors with anti-HER2 therapy on cell viability and apoptosis.</p>\u0000 <p><b>Results:</b> The study included 67 patients with a median age of 53 years. The overall pCR rate was 53.73%, with higher pCR rates observed in HR-negative patients compared to HR-positive patients (63.89% vs. 41.94%). Dual HER2 blockade with HLX02 and pertuzumab was associated with a numerically improved pCR rate (62.16%). ER expression significantly increased post-treatment, potentially indicating treatment resistance mechanisms. In vitro, the combination of CDK4/6 inhibitors with anti-HER2 therapy significantly reduced cell viability and promoted apoptosis in HR-positive, HER2-positive cell lines.</p>\u0000 <p><b>Conclusion:</b> HLX02 demonstrates real-world efficacy as part of neoadjuvant therapy for HER2-positive BC, especially in HR-negative patients. The lower pCR rate in HR-positive patients highlights the need for additional strategies. Combining CDK4/6 inhibitors with anti-HER2 therapy presents a promising approach for HR-positive HER2-positive patients, warranting further clinical validation.</p>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/1653319","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144598512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}